Literature DB >> 22398043

A functional polymorphism in UGT1A1 related to hyperbilirubinemia is associated with a decreased risk for Crohn's disease.

Hilbert S de Vries1, Rene H M Te Morsche, Kevin Jenniskens, Wilbert H M Peters, Dirk J de Jong.   

Abstract

BACKGROUND: An imbalance between the production of reactive oxygen species (ROS) and their capturing by antioxidants results in oxidative stress, this may play an important role in the pathogenesis of inflammatory bowel disease (IBD). Since bilirubin is an important endogenous antioxidant, increased levels of bilirubin may protect against IBD. UDP-glucuronosyltransferase 1A1 (UGT1A1) is the only enzyme involved in the conjugation of bilirubin and the common UGT1A1*28 allele in the UGT1A1 gene, which is strongly associated with Gilbert's syndrome in Caucasians, results in elevated plasma bilirubin levels. AIMS: To test the hypothesis that the UGT1A1*28 allele is associated with lower disease susceptibility to, and disease behavior within, IBD. In addition, a possible altered risk for developing IBD-drug related side-effects was explored.
METHODOLOGY: Genomic DNA of 751 patients with IBD (209 patients with ulcerative colitis and 542 patients with Crohn's disease) and 930 healthy controls was genotyped for the UGT1A1*28 promoter polymorphism, and genotype distribution was compared between patients and controls. Genotype phenotype interactions were also investigated.
RESULTS: Patients with Crohn's disease significantly less often bear the UGT1A1*28 homozygous genotype compared to the control group, with an odds ratio of 0.64, 95% CI: 0.42-0.98. The ulcerative colitis group showed no significant differences compared to controls.
CONCLUSION: The homozygous state of the UGT1A1*28 polymorphism, associated with higher serum bilirubin levels, may be protective for the development of Crohn's disease, suggesting that the anti-oxidant capacity of bilirubin may play a part.
Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22398043     DOI: 10.1016/j.crohns.2011.11.010

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  15 in total

1.  Bilirubin suppresses Th17 immunity in colitis by upregulating CD39.

Authors:  Maria Serena Longhi; Marta Vuerich; Alireza Kalbasi; Jessica E Kenison; Ada Yeste; Eva Csizmadia; Byron Vaughn; Linda Feldbrugge; Shuji Mitsuhashi; Barbara Wegiel; Leo Otterbein; Alan Moss; Francisco J Quintana; Simon C Robson
Journal:  JCI Insight       Date:  2017-05-04

2.  Association of serum bilirubin with aging and mortality.

Authors:  Brigid S Boland; Mamie H Dong; Ricki Bettencourt; Elizabeth Barrett-Connor; Rohit Loomba
Journal:  J Clin Exp Hepatol       Date:  2014-01-20

3.  Bilirubin prevents acute DSS-induced colitis by inhibiting leukocyte infiltration and suppressing upregulation of inducible nitric oxide synthase.

Authors:  Stephen D Zucker; Megan E Vogel; Tammy L Kindel; Darcey L H Smith; Gila Idelman; Uri Avissar; Ganesh Kakarlapudi; Michelle E Masnovi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-09-17       Impact factor: 4.052

Review 4.  CO and CO-releasing molecules (CO-RMs) in acute gastrointestinal inflammation.

Authors:  D Babu; R Motterlini; R A Lefebvre
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

5.  Evaluating the beneficial and detrimental effects of bile pigments in early and later life.

Authors:  Phyllis A Dennery
Journal:  Front Pharmacol       Date:  2012-06-22       Impact factor: 5.810

6.  Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease.

Authors:  Orazio Palmieri; Teresa M Creanza; Fabrizio Bossa; Orazio Palumbo; Rosalia Maglietta; Nicola Ancona; Giuseppe Corritore; Tiziana Latiano; Giuseppina Martino; Giuseppe Biscaglia; Daniela Scimeca; Michele P De Petris; Massimo Carella; Vito Annese; Angelo Andriulli; Anna Latiano
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325

7.  Bilirubin inhibits the up-regulation of inducible nitric oxide synthase by scavenging reactive oxygen species generated by the toll-like receptor 4-dependent activation of NADPH oxidase.

Authors:  Gila Idelman; Darcey L H Smith; Stephen D Zucker
Journal:  Redox Biol       Date:  2015-06-29       Impact factor: 11.799

8.  Bilirubin acts as an endogenous regulator of inflammation by disrupting adhesion molecule-mediated leukocyte migration.

Authors:  Megan E Vogel; Stephen D Zucker
Journal:  Inflamm Cell Signal       Date:  2016-02-15

9.  Reduced total serum bilirubin levels are associated with ulcerative colitis.

Authors:  Kathleen M Schieffer; Shannon M Bruffy; Richard Rauscher; Walter A Koltun; Gregory S Yochum; Carla J Gallagher
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

10.  Unconjugated Bilirubin Attenuates DSS-Induced Colitis Potentially via Enhancement of Bilirubin Reabsorption.

Authors:  Chong Zhao; Hongli Huang; Qiuhua Pan; Wenqi Huang; Wu Peng; Haoming Xu; Zhiqiang Feng; Yanlei Du; Yuqiang Nie; Yongjian Zhou
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.